Shorthill Samantha K, Klinger Finley R, Yusifov Aykhan, Thornburg Joshua P, Schmitt Marjie P, Mehl Emma R, Bettadapura Sharanya S, Agor Mason H, Teulé-Finley Florence, Cherrington Brian D, Bruns Danielle R
Kinesiology & Health, University of Wyoming, Laramie, Wyoming, United States.
Zoology and Physiology, University of Wyoming, Laramie, Wyoming, United States.
Am J Physiol Heart Circ Physiol. 2025 Jul 1;329(1):H271-H281. doi: 10.1152/ajpheart.00023.2025. Epub 2025 Jun 3.
Cardiac aging is sexually dimorphic, with women more likely than men to develop diastolic dysfunction for which no therapies exist. Loss of estrogen (E2) during menopause increases the risk of diastolic dysfunction in women through unclear mechanisms. Citrullination, a posttranslational modification catalyzed by peptidylarginine deiminase 2 (PAD2), is positively regulated by E2, suggesting a novel mechanism linking PAD2, diastolic function, and E2 in the female heart. We hypothesized that PAD2 expression and citrullination are sexually dimorphic with aging such that as E2 levels decline, so does PAD2 expression and citrullination, contributing to diastolic dysfunction. PAD2 expression decreased with age in female mice but not in the aging male heart. Mass spectrometry detected citrullination of sarcomeric and metabolic proteins, with lower levels of citrullinated proteins in aged female hearts compared with young. To confirm direct regulation of PAD2 by E2, a cohort of young (2 mo) and aged (21 mo) mice underwent ovariectomy with or without E2 replacement. Contrary to our hypothesis, PAD2 expression was not regulated by E2 in the heart. To directly link PAD2 and diastolic function, we assessed cardiac function in middle-aged female global PAD2 knockout mice and found that loss of PAD2 resulted in diastolic dysfunction. Together, we establish that protein citrullination and PAD2 decline with age in the female heart, perhaps contributing to diastolic dysfunction. Elucidation of the mechanisms underlying PAD2 declines in the female heart remains to be determined and may benefit the development of therapies for diastolic dysfunction for aging women. We tested peptidylarginine deiminase 2 (PAD2) as a novel regulator of diastolic dysfunction in the aging female heart. We found that PAD2 expression declines with age in the female heart and loss of PAD2 causes diastolic dysfunction. However, unlike in female reproductive tissue, PAD2 in the heart is not regulated by estrogen. Given the large burden of diastolic dysfunction in aging women, future work to understand the regulation of PAD2 and diastolic dysfunction is warranted.
心脏衰老具有性别差异,女性比男性更易发生舒张功能障碍,而目前尚无针对该病症的治疗方法。绝经期间雌激素(E2)的丧失通过尚不明确的机制增加了女性舒张功能障碍的风险。瓜氨酸化是一种由肽基精氨酸脱氨酶2(PAD2)催化的翻译后修饰,受E2正向调控,提示在雌性心脏中存在一种将PAD2、舒张功能和E2联系起来的新机制。我们推测,随着年龄增长,PAD2表达和瓜氨酸化具有性别差异,即随着E2水平下降,PAD2表达和瓜氨酸化也随之降低,从而导致舒张功能障碍。在雌性小鼠中,PAD2表达随年龄下降,但在雄性心脏衰老过程中并非如此。质谱分析检测到肌节蛋白和代谢蛋白的瓜氨酸化,与年轻雌性心脏相比,老年雌性心脏中瓜氨酸化蛋白水平较低。为了证实E2对PAD2的直接调控作用,对一组年轻(2月龄)和老年(21月龄)小鼠进行了卵巢切除术,并给予或不给予E2替代治疗。与我们的假设相反,心脏中PAD2表达不受E2调控。为了直接将PAD2与舒张功能联系起来,我们评估了中年雌性全基因组PAD2敲除小鼠的心脏功能,发现PAD2缺失导致舒张功能障碍。我们共同确定,在雌性心脏中,蛋白质瓜氨酸化和PAD2随年龄下降,这可能导致舒张功能障碍。雌性心脏中PAD2下降的潜在机制仍有待确定,这可能有助于开发针对老年女性舒张功能障碍的治疗方法。我们将肽基精氨酸脱氨酶2(PAD2)作为老年雌性心脏舒张功能障碍的一种新型调节因子进行了测试。我们发现,在雌性心脏中,PAD2表达随年龄下降,且PAD2缺失会导致舒张功能障碍。然而,与雌性生殖组织不同,心脏中的PAD2不受雌激素调控。鉴于老年女性舒张功能障碍的负担较重,未来有必要开展工作来了解PAD2与舒张功能障碍的调控关系。